36516

Therapeutic Apheresis with Extracorporeal Immunoadsorption and Plasma Reinfusion

Therapeutic apheresis (36516) is a sophisticated extracorporeal blood purification procedure designed to remove specific pathogenic components from a patient's plasma while returning the rest of the blood components back to the patient's circulation. Unlike standard plasmapheresis where plasma is discarded and replaced with albumin or fresh frozen plasma, immunoadsorption involves passing the patient's plasma through a medical device containing a column or filter coated with specific ligands, such as Protein A or specific antigens and antibodies. These ligands selectively bind and remove targeted immunoglobulins, immune complexes, or specific proteins associated with severe autoimmune or hematological disorders. The procedure begins with the establishment of venous access, typically through a dual-lumen catheter or two large-bore peripheral veins. The patient's blood is pumped into an apheresis machine where centrifugal or membrane-based separation divides the whole blood into cellular components (red cells, white cells, platelets) and plasma. The plasma is then directed through the immunoadsorption column. Once the pathogenic substances are filtered out, the purified plasma is recombined with the cellular components and reinfused into the patient. This selective removal allows for the treatment of larger volumes of plasma without the need for exogenous replacement fluids, reducing the risk of transfusion-related reactions or electrolyte imbalances. It is frequently utilized in severe, refractory cases of autoimmune conditions or organ transplant rejection where specific antibody removal is critical to the patient's recovery and stabilization.

Clinical Indications

  • Refractory Myasthenia Gravis with exacerbation
  • Goodpasture Syndrome with pulmonary hemorrhage or renal failure
  • Systemic Lupus Erythematosus (SLE) with severe organ involvement
  • Hemophilia with high-titer Factor VIII or IX inhibitors
  • Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barre Syndrome)
  • Antibody-Mediated Rejection (AMR) in solid organ transplant (e.g., kidney, heart)
  • Severe Pemphigus Vulgaris refractory to standard therapy
  • Refractory Thrombocytopenic Purpura (TTP)
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Homozygous Familial Hypercholesterolemia (selective cases)

Procedure Steps

  1. Verify patient identity and confirm informed consent for the apheresis procedure.
  2. Establish adequate vascular access, either via a large-bore dual-lumen central venous catheter or high-flow peripheral veins.
  3. Connect the patient to the apheresis system and prime the tubing and the immunoadsorption column according to manufacturer specifications.
  4. Initiate blood flow, separating the whole blood into cellular components and plasma using centrifugal or membrane filtration.
  5. Divert the separated plasma through the extracorporeal immunoadsorption column containing specific ligands.
  6. Continuously monitor vital signs and anticoagulation parameters (e.g., ionized calcium if using citrate or ACT if using heparin).
  7. Direct the treated plasma back to the system to be recombined with the cellular components (RBCs, WBCs, platelets).
  8. Reinfuse the processed, purified whole blood back into the patient's venous circulation.
  9. Continue the cycle until the prescribed volume of plasma has been processed through the adsorption device.
  10. Conclude the procedure, disconnect the patient, and ensure hemostasis at the access site.
  11. Document the total blood and plasma volume processed, anticoagulation used, and patient tolerance.

Coding Guidelines

  • Do not report 36516 in conjunction with other therapeutic apheresis codes (36511-36514, 36515, 36522) for the same session.
  • If a separate Evaluation and Management (E/M) service is provided on the same day, it must be significant and separately identifiable to be reported with modifier 25.
  • The placement of a central venous catheter for apheresis access is not bundled and should be reported separately using the appropriate CPT code (e.g., 36556).
  • HCPCS codes for the specific adsorption column (e.g., A4690) and medications (e.g., heparin, citrate) should be checked for separate reimbursement eligibility based on the payer and setting.
  • 36516 describes a selective process where plasma is reinfused; it should not be used for plasma exchange (36514) where plasma is replaced with donor fluid.

Associated ICD-10 Codes